Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

VIMRxyn to undergo phase I in glioma patients

Aug. 23, 1996

NeXstar describes ELONA and significance for VEGF inhibitor development

Aug. 23, 1996

Shionogi reports ras transformation inhibitor

Aug. 23, 1996

Farnesyl transferase inhibitors from Pierre Fabre

Aug. 23, 1996

Study indicates ISIS-3521/CGP-64128A inhibits tumor growth

Aug. 23, 1996

IDEC-Y2B8/IDEC-C2B8 combination undergoes phase I/II

Aug. 23, 1996

Fareston launched in the U.K.

Aug. 23, 1996

Phase I pharmacokinetic study of asulacrine initiated

Aug. 23, 1996

Japanese investigators describe antileukemia activity of drupangtonine

Aug. 23, 1996

Taiho discloses antitumor nucleoside drugs

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 11, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 11, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.